earnings
confidence high
sentiment negative
materiality 0.75
BioMarin estimates FY2025 revenue ~$3.2B; expects $230-260M ROCTAVIAN asset write-down
BIOMARIN PHARMACEUTICAL INC
2025-FY EPS reported
$1.80
revenue$3,221,253,000
- Preliminary FY2025 total revenue ~$3.2B, with VOXZOGO contributing ~$920M.
- ROCTAVIAN asset write-down of ~$230-260M in Q4 2025; $0.60-$0.64 non-GAAP EPS impact.
- Excluding write-down, previous FY2025 non-GAAP EPS guidance unchanged.
- Approximately 200M weighted-average diluted shares outstanding assumed.